^
Association details:
| Biomarker: | PD-L2 overexpression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | paclitaxel (Tubulin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biological Function of PD-L2 and Correlation with Overall Survival in Type II Endometrial Cancer
Published date:
05/28/2021
Excerpt:
As confirmed by the in silico analysis, PD-L2 was more expressed than PD-L1 in EC cell lines. PD-L2 was found highly expressed in 64.44% of tumor specimens...In vitro PD-L2 enhanced migratory ability of EC cells, influenced AKT/mTOr and ERK pathways and response to Paclitaxel.